Biotech startup Neumora, launched by prominent venture firm ARCH Venture Partners, has ceased development of its depression treatment program. The decision was reported by STAT News in its latest biotech roundup.
The move marks a significant setback for the company, which had been pursuing novel approaches to treating major depressive disorder. The program's termination raises questions about the viability of the therapeutic target Neumora was pursuing.
ARCH Venture Partners had placed substantial backing behind Neumora, though the exact financial impact of the halted program has not been disclosed. The company had not yet advanced the depression candidate into late-stage clinical trials.
For patients with treatment-resistant depression, the discontinuation narrows the pipeline of potential new therapies. The setback may also prompt investors to scrutinize other early-stage neuroscience programs backed by venture capital.
Further details on the specific reasons for the program's termination were not provided by the company or ARCH Venture Partners at the time of reporting.